RxDoctor Payments DataLook up a doctor →

Annette Fontaine, MD

Medical Oncology · Albuquerque, NMNPI 1346234788

Payments from drug & device makers

$297,662in general payments, 2019–2025

Across 322 payments — averaging $924.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$88K
  • Merck$84K
  • AstraZeneca$31K
  • Stemline Therapeutics Inc.$19K
  • E.r. Squibb & Sons, L.L.C.$12K
  • Incyte Corporation$10K
  • plus $54K from 45 others

What the payments were for

  • Consulting fees$168,29881%
  • Speaking & faculty fees$23,66011%
  • Travel & lodging$9,9655%
  • Food & beverage$5,4913%
  • Education$4400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few medical oncology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,830,694
Medicare patients
676
Services billed
96,870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib51$801,636
JakafiRuxolitinib Phosphate33$585,343
Lenalidomide25$415,698
KisqaliRibociclib Succinate23$284,937
RevlimidLenalidomide13$276,127
VerzenioAbemaciclib18$266,588
NerlynxNeratinib Maleate11$243,433
ImbruvicaIbrutinib14$118,218
XareltoRivaroxaban68$62,468
XtandiEnzalutamide13$54,949
EliquisApixaban33$22,534
Exemestane46$3,422
Anastrozole98$2,855
Letrozole91$2,039
Tamoxifen Citrate64$1,728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$5,595$824,17084 claims
Incyte CorporationJakafi$10,019$585,34333 claims
Puma Biotechnology, Inc.Nerlynx$305$243,43311 claims
Johnson & JohnsonXarelto$2,709$62,46868 claims
Astellas Pharma US IncXtandi$7,573$54,94913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in New Mexicoon file to place this against a meaningful peer group, so we don't.

Other medical oncology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →